Compare WAY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | TLX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2023 | N/A |
| Metric | WAY | TLX |
|---|---|---|
| Price | $22.38 | $10.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $36.59 | $21.13 |
| AVG Volume (30 Days) | ★ 2.7M | 146.1K |
| Earning Date | 04-29-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 569.23 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,099,278,000.00 | N/A |
| Revenue This Year | $18.26 | N/A |
| Revenue Next Year | $10.62 | N/A |
| P/E Ratio | ★ $98.09 | $150.33 |
| Revenue Growth | ★ 16.50 | N/A |
| 52 Week Low | $17.26 | $6.28 |
| 52 Week High | $39.99 | $14.27 |
| Indicator | WAY | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 43.37 |
| Support Level | $21.03 | $10.12 |
| Resistance Level | $26.73 | $11.38 |
| Average True Range (ATR) | 0.99 | 0.26 |
| MACD | -0.15 | -0.16 |
| Stochastic Oscillator | 45.24 | 3.74 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.